GlobeNewswire Inc.··NaZymeworks Wins FDA Fast Track for Cancer Drug ZW191, Accelerating Path to Market
Zymeworks secures FDA Fast Track designation for ZW191, an ovarian cancer antibody-drug conjugate, accelerating development timelines.
ZYMEantibody-drug conjugatePhase 1 clinical trial